Instil Bio, Inc. is a biotechnology company focused on developing innovative cell therapies for the treatment of cancer
The company specializes in harnessing the power of tumor-infiltrating lymphocytes (TILs), a type of immune cell that has the potential to recognize and attack tumor cells. By utilizing advanced manufacturing processes and proprietary technologies, Instil Bio aims to create personalized treatment options tailored to the unique characteristics of each patient's cancer. Their research efforts are geared towards improving outcomes for patients suffering from various types of malignancies, with the goal of delivering safe and effective therapies that can ultimately enhance the quality of life.
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.
Gainers Kala Pharmaceuticals, Inc. (NASDAQKALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
